))
Early-Stage Non–Small Cell Lung Cancer: Answers to Frequently Asked Questions
Manage episode 423438379 series 3456244
Content provided by i3 Health and I3 Health. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by i3 Health and I3 Health or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this video, Dr. Jamie E. Chaft, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, answers questions asked by the audience during her CME/NCPD–approved activity with i3 Health, Leveraging the Growing Arsenal of Therapies for Early-Stage Non–Small Cell Lung Cancer (NSCLC), chaired by Dr. Helena Yu. Dr. Chaft shares insights into emerging roles of measurable residual disease (MRD) in lung cancer, the significance of the recent approval of alectinib for ALK-positive disease, treatment considerations for older versus younger patients, important research updates at the American Society of Clinical Oncology (ASCO) Annual Meeting, and more! Interested in completing this activity and earning FREE CME/NCPD credit? Click here: https://bit.ly/4b3QDXJ
…
continue reading
31 episodes
Share
